Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06015282 · ClinicalTrials.gov registry record · Phase 3
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older
A Phase 3 study, sponsored by Seqirus.
- Completed
- Registry status
- Phase 3
- Development phase
- 7,741
- Enrollment target
NCT06015282: Completed Phase 3 study, sponsored by Seqirus.
NCT06015282 is a Phase 3 study that has completed, run by Seqirus. The registered enrollment target is 7,741 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (904% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06015282, a Phase 3 study, has completed, sponsored by Seqirus.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 7,741 participants
- Enrollment target
Study Summary
This is a Phase 3, randomized, parallel-group, comparator-controlled, observer-blind, multicenter study of immunogenicity and safety in approximately 7700 male and female adults aged 50 years and older (approximately equally split between two age groups: 50-64 years; 65 years and older), who are healthy or have stable comorbidities that increase their risk of complications from influenza infection. Three lots of aQIVc will be evaluated for consistency and pooled for the comparison with the 2 control vaccines. Subjects will be randomly assigned to receive 1 of 3 lots of aQIVc, QIVr, or aQIV in a 1:1:1:2:2 ratio (for a 3:2:2 ratio for aQIVc, QIVr, and aQIV). The study will have a treatment period (Day 1 to Day 29) and a follow-up period (Day 30 up to Day 181); a subset of 770 subjects will be followed up up to Day 365.
Primary Outcome
HI assay will be measured using cell-derived target viruses for the A/H1N1, A/H3N2, B/Yamagata, and B/Victoria vaccine strains.
Interventions
- BIOLOGICAL Investigational aQIVc
- BIOLOGICAL licensed QIVr
- BIOLOGICAL licensed aQIV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,741 participants |
| Start Date | 2023-11-03 |
| Est. Completion | 2025-01-30 |
| Phase | Phase 3 |
What the finished NCT06015282 record still lists
NCT06015282 is an interventional study that assigns participants to a tested intervention. Its 7,741 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (904% higher).
The record links to 0 conditions, and to 3 interventions - of which Investigational aQIVc is the first listed.
NCT06015282 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06015282 about?
NCT06015282 is a clinical study titled "The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older". This is a Phase 3, randomized, parallel-group, comparator-controlled, observer-blind, multicenter study of immunogenicity and safety in approximately 7700 male and female adults aged 50 years and older (approximately equally split between two age groups: 50-64 years; 65 years and older), who are hea...
What is the current status of trial NCT06015282?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 7,741 participants. The study started on 2023-11-03. Estimated completion is 2025-01-30.
What interventions are being tested in trial NCT06015282?
The interventions under investigation include: Investigational aQIVc (BIOLOGICAL), licensed QIVr (BIOLOGICAL), licensed aQIV (BIOLOGICAL).
Who is sponsoring clinical trial NCT06015282?
This trial is sponsored by Seqirus, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06015282's enrollment target sits among peer trials
7,741 33rd of 2000 higher than 1,968 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06560398 · 7,649 participants · NA
Working Through Outreach, Navigation and Digital Enabled Referral and Recruitment Strategies (ACT WONDER²S)
- NCT03848312 · 7,600 participants · Phase 3
Preventing Alzheimer's With Cognitive Training
- NCT00439049 · 7,500 participants
Substance Abuse Pre-Treatment Screening Study
- NCT04809740 · 7,500 participants · NA
Evaluating the Implementation and Impact of Navigator-delivered ePRO System
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI